POOLBEG PHARMA PLC - $POLBF STOCK NEWS

Poolbeg Pharma PLC has announced its results for the year ended 31 December 2023, highlighting significant pipeline advancements, expansion into cancer immunotherapy-induced CRS, and key management hires. Financially, the company reported a cash balance of £12.2 million and appointed industry veteran Professor Brendan Buckley as a Non-Executive Director. Operationally, positive results were seen from the POLB 001 LPS human challenge trial, and strategic expansions and collaborations were made to strengthen the company's portfolio. Post-period end, positive in vivo data confirmed the efficacy of POLB 001 in reducing cancer immunotherapy-induced CRS, positioning the company well for future success.

Poolbeg Pharma PLC announced the appointment of Shore Capital Stockbrokers as its Joint Broker, with Cavendish Capital Markets remaining as the Nominated Adviser and Joint Broker alongside J&E Davy. The company focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs.

Poolbeg Pharma PLC has announced an option agreement to acquire an orphan drug candidate for Behçet's Disease. The exclusive 12-month option agreement with Silk Road Therapeutics Inc is for a novel topical muco-adherent formulation of Pentoxifylline (tPTX) to treat oral ulcers in patients with Behçet's Disease. The drug has completed a successful Phase 2 trial, demonstrating superiority over the current standard of care. It has secured Orphan Drug Designation and Fast Track Designation from the FDA, positioning it for a potential 505(b)(2) approval pathway in the U.S.

Poolbeg Pharma PLC has announced a TR-1 notification of major holdings, with Michael Kelly holding 4.8% of voting rights attached to shares, as of 15th March 2024. The press release provides details on the notification, including the reason, persons subject to the notification obligation, and the resulting situation on the date of the threshold being crossed or reached. This indicates a significant development in the company's shareholder structure, potentially influencing decision-making and corporate governance.

Poolbeg Pharma (POLBF) receives a Notice of Allowance for its Immunomodulator II patent application in the United States, strengthening its intellectual property portfolio. The patent covers the potential use of POLB 001, a Phase II-ready p38 MAP kinase inhibitor, in treating hypercytokinaemia and preventing cytokine storms. This development enhances the company's value for potential pharma partners and expands its patent portfolio, particularly in cancer immunotherapies. CEO Jeremy Skillington highlights the significance of this milestone, emphasizing the potential market impact and the unmet medical need in cancer immunotherapy-induced Cytokine Release Syndrome.

Poolbeg Pharma (POLBF) CEO Jeremy Skillington purchases 154,764 ordinary shares, representing 0.17% of the company's issued share capital. The purchase was made at a price of 10.8 pence per share, indicating confidence in the company's future.

Poolbeg Pharma announces Cathal Friel's purchase of 830,000 ordinary shares at 11.68 pence per share, increasing his stake to 7.4% of the Company's issued share capital.

Poolbeg Pharma announces a change in Board role and approval of an Employee Performance Incentive Plan. Cathal Friel becomes Executive Chairman, and an EIP is adopted to align objectives with shareholders. The plan awards long-term incentive options to key senior management. The company focuses on rare diseases and profitable revenues, with a strong management team in place for growth and value creation.

Poolbeg Pharma announces a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS, supported by independent research. The company aims to focus on Rare and Orphan Diseases, leveraging the expertise of the former Amryt team. POLB 001 shows promise in addressing CRS induced by CAR-T and BsAb treatments, with potential cost-saving benefits and improved patient access to therapies.